Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143284 | 0.94 | KDR (0.65) | KDRCHEK1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL140728 | 0.84 | KDR (0.50) | KDRCHEK1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5370412 | 0.79 | SLC6A2 (0.62) | KDRCHEK1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5354782 | 0.76 | KDR (0.65) | KDRCHEK1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6333156 | 0.74 | KDR (0.70) | KDRCHEK1 | |
| SCHEMBL144967 | 0.73 | KDR (1.00) | KDRCHEK1 | |
| SCHEMBL5354528 | 0.73 | KDR (0.50) | KDRCHEK1SLC6A4SLC6A2 | |
| SCHEMBL5079326 | 0.72 | CHEK1 (0.54) | KDRCHEK1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL142898 | 0.71 | HTR2C (0.57) | KDRCHEK1 | |
| SCHEMBL3065696 | 0.70 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927293-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-08-09 | — | — | US | claimed |
| US-20040235826-A1 | Tyrosine kinase ihnibitors | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | claimed |
| US-20040192725-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-09-30 | — | — | US | claimed |
| WO-2003020276-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| US-6927293-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-08-09 | — | — | US | disclosed |
| US-20040235826-A1 | Tyrosine kinase ihnibitors | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| US-20040192725-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2003020276-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235826-A1 | Tyrosine kinase ihnibitors | KDR, FLT4, ERBB2 | KDR 1/4885CHEK1 955/4885SLC6A4 4367/4885 |
| US-20040192725-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885SLC6A4 4618/4885 |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | KDR 1077/4885CHEK1 3154/4885SLC6A4 4772/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | KDR 1077/4885CHEK1 3154/4885SLC6A4 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.